Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Creative Planning

Creative Planning raised its position in Moderna, Inc. (NASDAQ:MRNA) by 115.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 34,710 shares of the company’s stock after purchasing an additional 18,593 shares during the quarter. Creative Planning’s holdings in Moderna were worth $13,358,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the business. Corbenic Partners LLC acquired a new stake in Moderna during the 3rd quarter worth approximately $25,000. Evermay Wealth Management LLC acquired a new stake in Moderna during the 2nd quarter worth approximately $28,000. Girard Partners LTD. acquired a new stake in Moderna during the 3rd quarter worth approximately $29,000. Focused Wealth Management Inc acquired a new stake in Moderna during the 3rd quarter worth approximately $38,000. Finally, Guidance Point Advisors LLC acquired a new stake in Moderna during the 3rd quarter worth approximately $40,000. Institutional investors own 59.11% of the company’s stock.

In other news, insider Juan Andres sold 5,000 shares of Moderna stock in a transaction dated Wednesday, October 20th. The shares were sold at an average price of $333.90, for a total transaction of $1,669,500.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction that occurred on Thursday, January 13th. The shares were sold at an average price of $219.56, for a total transaction of $3,293,400.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 419,000 shares of company stock valued at $118,092,130. Insiders own 19.40% of the company’s stock.

A number of research analysts recently commented on the stock. Jefferies Financial Group dropped their target price on shares of Moderna from $375.00 to $325.00 and set a “hold” rating on the stock in a research report on Friday, November 5th. SVB Leerink reaffirmed a “sell” rating on shares of Moderna in a research report on Thursday, December 23rd. Wolfe Research initiated coverage on shares of Moderna in a research report on Monday, November 8th. They set an “outperform” rating and a $304.00 price objective on the stock. TheStreet raised shares of Moderna from a “c+” rating to a “b-” rating in a research report on Monday, November 1st. Finally, Cowen initiated coverage on shares of Moderna in a research report on Monday, December 6th. They set a “market perform” rating and a $250.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $251.81.

NASDAQ:MRNA opened at $204.73 on Friday. The company has a market capitalization of $83.01 billion, a P/E ratio of 12.55, a price-to-earnings-growth ratio of 0.28 and a beta of 1.22. Moderna, Inc. has a twelve month low of $117.34 and a twelve month high of $497.49. The company has a current ratio of 1.35, a quick ratio of 1.25 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $259.66 and a two-hundred day moving average price of $320.60.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings results on Thursday, November 4th. The company reported $7.70 EPS for the quarter, missing analysts’ consensus estimates of $9.49 by ($1.79). The firm had revenue of $4.97 billion for the quarter, compared to analysts’ expectations of $6.29 billion. Moderna had a return on equity of 121.61% and a net margin of 59.69%. The business’s quarterly revenue was up 3065.0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.59) earnings per share. On average, equities research analysts predict that Moderna, Inc. will post 26.32 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

Read More: If I purchase shares through a brokerage account, am I the holder of record?

Institutional Ownership by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.